The incidence of ICI-related pneumonitis was reported to be 2.5–5% with anti-PD-1/PD-L1 monotherapy and 7–10% with anti-CTLA-4/anti-PD-1 combination therapy [45]. This evidence concerns the gene CTLA4 and pneumonitis.